MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Marker Therapeutics Retained Earnings 2011-2026 | MRKR
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Marker Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -459 M | -447 M | -436 M | -428 M | -398 M | -356 M | -328 M | -306 M | -157 M | -146 M | -134 M | -86.3 M | -55.4 M | -49.6 M | -43.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.7 M | -459 M | -255 M |
Quarterly Retained Earnings Marker Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -457 M | -455 M | -451 M | -447 M | -443 M | -441 M | -439 M | -436 M | -433 M | -431 M | -433 M | -428 M | -424 M | -417 M | -408 M | -398 M | -388 M | -376 M | -365 M | -356 M | -356 M | -356 M | -356 M | -328 M | -328 M | -328 M | -328 M | -306 M | -306 M | -306 M | -306 M | -157 M | -157 M | -157 M | -157 M | -146 M | -146 M | -146 M | -146 M | -134 M | -134 M | -134 M | -134 M | -86.3 M | -86.3 M | -86.3 M | -86.3 M | -55.4 M | -58.3 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -58.3 K | -457 M | -289 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Verastem
VSTM
|
-1.16 B | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
-408 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-1.36 B | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenon Pharmaceuticals
XENE
|
-899 M | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
-617 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
-510 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
-2.29 B | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.38 B | $ 4.29 | -3.6 % | $ 822 M | Canada |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-377 M | - | - | $ 1.41 B | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 19.01 | -2.66 % | $ 889 M | USA |
 |
Gritstone Oncology
GRTS
|
-660 M | - | 0.42 % | $ 213 M | USA |
 |
Завод ДИОД
DIOD
|
1.21 B | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-3.54 B | - | - | - | Russia |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 20.75 | -3.35 % | $ 3.44 B | USA |
 |
Aligos Therapeutics
ALGS
|
-642 M | $ 6.66 | -5.4 % | $ 65.8 M | USA |
 |
Teligent, Inc.
TLGT
|
-121 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-427 M | - | - | $ 2.91 B | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alkermes plc
ALKS
|
-735 M | $ 29.39 | -1.77 % | $ 4.84 B |  Irlanda |
 |
Cabaletta Bio
CABA
|
-517 M | $ 2.68 | -4.96 % | $ 269 M | USA |
 |
AbbVie
ABBV
|
-15.5 B | $ 209.4 | -0.81 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Athira Pharma
ATHA
|
-406 M | - | - | $ 269 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |